Header image

Concurrent Session 5B: Heroin & Opioids

Tracks
.
Wednesday, November 15, 2017
9:00 AM - 10:15 AM
Grand Ballroom 3

Speaker

Agenda Item Image
Miss Louise Geddes
PhD Student
The Kirby Institute

Intravenous Fentanyl Use Among People Who Inject Drugs In Australia

9:00 AM - 9:15 AM

Abstract

Speaker Presentation

Biography

Louise Geddes is a Research Assistant and PhD candidate at the Kirby Institute, UNSW. Louise currently works on New South Wales NSP Enhanced Data Collection project which collects data from NSP attendees in NSW. Her particular research interest is opioid use among people who inject drugs.
Agenda Item Image
Ms Consuelo Rivas
Research Nurse
Seslhd/The Langton Centre

Lack of analgesic efficacy of opioids and gabapentin on acute experimental pain responses in methadone maintained patients

9:15 AM - 9:30 AM

Abstract

Speaker Presentation

Biography

Ms Consuelo Rivas (RN) has been a Research Nurse in SESLHD Drug and Alcohol Services at The Langton Centre for 7 years, working in different projects both in the areas of Clinical Trials and non-Clinical Trials, as well as collaborating with other Local Health Districts in different research projects. Consuelo is currently undertaking a Masters in Clinical Epidemiology, and is particularly interested in the area of Biostatistics and its application within Drug and Alcohol Services.
Mr. Joshua Garfield
Research Officer
Turning Point

Changes In Illicit Opioid Use Predict Changes In Anhedonia In Opioid-Dependent Individuals – A Longitudinal Analysis

9:30 AM - 9:45 AM

Abstract

Speaker Presentation

Biography

Joshua Garfield is a research officer for Monash University, based at Turning Point. He received his PhD from the University of New South Wales in 2008, where he studied the behavioural neuroscience of animal learning and memory. Following this, he assisted with several studies of brain stimulation treatments for depression before moving to Melbourne in 2011, where he has managed several studies related to the psychology of opioid dependence and cognitive training treatments for alcohol dependence.
Agenda Item Image
Dr. Barbara Haight
Senior Director, Medicines Development Leader
Indivior Inc.

RBP-6000 Buprenorphine Monthly Depot Demonstrates Efficacy, Safety, and Exposure/Response Relationship in Opioid Use Disorder

9:45 AM - 10:00 AM

Abstract

Speaker Presentation

Biography

Barbara R. Haight holds the position of Senior Director, Medicines Development Leader in the opioid use disorder therapeutic area at Indivior, Inc. She has 19 years of industry experience in Clinical Development, Clinical Safety and Pharmacovigilance, and Medical Affairs. She received her Bachelor of Science from the University of North Carolina and Doctor of Pharmacy from Mercer University.
Professor Nicholas Lintzeris
Director, D&a Services
Seslhd

Long-Term Safety, Tolerability And Effectiveness Of Weekly And Monthly Buprenorphine Depots For Opioid Use Disorder

10:00 AM - 10:15 AM

Abstract

Biography

Professor Lintzeris has worked as a clinician and researcher in addiction medicine for over 25 years. He is the Director of D&A Services for South East Sydney LHD and Clinical Director of the Lambert Initiative in Cannabinoid Therapeutics at the University of Sydney. He is a leading author of the Australian clinical guidelines for opioid treatment and the Australian Opioid Substitution Training Programme for medical practitioners, and has served as Chief Addiction Medicine Specialist for the NSW Ministry of Health.

Chair Person

Agenda Item Image
Gabriele Fischer
Leader Of Addiction Clinic
Medical University Vienna

 

loading